Skip to main content
OpenTrials
Completed

NCT Number: NCT04999566

Cardiac Manifestation and Inherited Metabolic Diseases

The aim of this study is to report and describe cardiac manifestations associated with IMD in a cohort of patients followed in a reference center for rare diseases (Lausanne University Hospital, CHUV) from 2017-2020.

Completed

Looking for future studies?

Notify Me

Key information

Age range

16 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Lausanne University Hospital

Lausanne, Canton of Vaud, 1011, Switzerland

About this study

Inherited metabolic diseases (IMD) are genetic disorders resulting from an enzyme defect and/or transport proteins in metabolic pathways affecting proteins, fat, carbohydrate metabolism or impaired organelle function. As IMDs can affect the primary sources of energy (glycogen, fatty acids), they can lead to cardiac dysfunction. Although most of IMDs are multisystemic diseases, in some cases, the cardiac dysfunction they cause is the main clinical feature and source of major complications which will determine the prognosis, like heart failure, ventricular arrythmias or even sudden death. Information regarding cardiac manifestations in adult IMDs is currently scarce and little is known about their clinical and radiological characteristics.

A database was created in 2017 including all patients with IMD followed at the Adult Metabolic Clinic in the CHUV. This database was part of a protocol submitted and approved by the Ethics committee (# 2017-02328). The results of this first analysis were published in the Journal of Orphan Rare Diseases. Investigators will use this database to identify all the patients who had cardiac examination. Only patients from the Lausanne University Hospital followed jointly with the Division of Cardiology will be included in the analysis. Electronic and paper patient charts from the Division of Genetic Medicine and Division of Cardiology (Lausanne University Hospital) will be reviewed for type of IMD and cardiac investigations (cardiac ultrasound, multiple resonance Imaging, electrocardiogram). All variables will be entered in an excel database.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All IMD adult patients followed at the adult metabolic clinic at the Lausanne University Hospital from 2017 to 2020 with cardiac investigations

Exclusion criteria

  • Age < 16 years. Any document attesting a refusal to participate will exclude the data entry of the concerned patient

Treatment and study plan

Primary outcomes

  1. Specific diagnosis of Inborn Errors of Metabolism listed by their frequency

    Time frame: Day 1

    Clinical outcome

  2. Age at diagnosis (years/months)

    Time frame: Day 1

    Clinical outcome

  3. Current age (years/months)

    Time frame: through study completion, an average of 1 year

    Clinical outcome

  4. Weight (kg)

    Time frame: through study completion, an average of 1 year

    Clinical outcome

  5. Height (cm)

    Time frame: through study completion, an average of 1 year

    Clinical outcome

  6. BMI (kg/m^2)

    Time frame: through study completion, an average of 1 year

    Clinical outcome. Weight and height will be combined to report BMI

  7. Cardiac involvement

    Time frame: 3 years

    Type of complications (restrictive cardiomyopathy, hypertrophic cardiomyopathy, dilated cardiomyopathy, arrythmia, heart failure, valvlulopathy, cardiomegaly, thrombosis)

  8. Left ventricular mass (g/m^2)

    Time frame: 3 years

    Cardiac ultrasound and multiple resonance imaging description of left ventricular mass

  9. Left ventricular volume (cc/m^2)

    Time frame: 3 years

    Cardiac ultrasound and multiple resonance imaging description of left ventricular volume

  10. Right ventricular volume (cc/m^2)

    Time frame: 3 years

    Cardiac ultrasound and multiple resonance imaging description of right ventricular volume

  11. Left ventricular diameter (mm)

    Time frame: 3 years

    Cardiac ultrasound and multiple resonance imaging description of left ventricular diameter

  12. Left ventricular ejection fraction (%)

    Time frame: 3 years

    Cardiac ultrasound and multiple resonance imaging description of left ventricular ejection fraction

  13. Right ventricular ejection fraction (%)

    Time frame: 3 years

    Cardiac ultrasound and multiple resonance imaging description of right ventricular ejection fraction

  14. aortic root diameter (mm)

    Time frame: 3 years

    Cardiac ultrasound and multiple resonance imaging description of aortic root diameter

  15. Additional cardiac investigations

    Time frame: 3 years

    ECG-QT interval

Secondary outcomes

  1. Specific treatment for inherited metabolic diseases

    Time frame: 3 years

    Treatment specific to each diseases including ammonia scavenger, enzyme replacement therapy, vitamin cofactors

  2. Gender (Male/Female)

    Time frame: Day 1

    Demography outcome

Sponsors and collaborators

Lead sponsor

University of Lausanne

Other

Registry information

Official study title

Cardiac Manifestations in Adult Patients With Inherited Metabolic Disease: a Case Series

Important dates

Study start
2021
Primary completion
2023
Study completion
2024
First posted
Aug 11, 2021
Registry last updated
Dec 4, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.